TRAX First Tracks Biotherapeutics, Inc.
Fundamentals / CIK 0002091349 / USDFirst Tracks Biotherapeutics, Inc. reported $170.5M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open TRAX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$155.6M Total debt: $3.77M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $23.85M | $25.64M | $33.95M | $33.32M | $39.27M | $41.47M |
| Total Operating Expenses | $32.84M | $34.94M | $52.81M | $45.06M | $45.90M | $51.28M |
| Operating Income | -$32.84M | -$34.94M | -$52.81M | -$45.06M | -$45.90M | -$51.28M |
| EBITDA | -$32.75M | -$34.83M | -$52.69M | -$44.92M | -$45.76M | -$51.13M |
| Interest Income | $1.50M | $1.56M | $2.33M | $3.20M | $3.47M | $4.09M |
| Net Income | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M | -$47.20M |
| Basic EPS | -$0.88 | -$0.95 | -- | -$1.50 | -$1.47 | -- |
| Diluted EPS | -$0.88 | -$0.95 | -- | -$1.50 | -$1.47 | -- |
| Basic Shares Outstanding | 35.7M | 35.0M | -- | 27.8M | 28.8M | -- |
| Diluted Shares Outstanding | 35.7M | 35.0M | -- | 27.8M | 28.8M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $155.6M | $168.0M | $248.5M | $238.2M |
| Short-Term Investments | $0 | $0 | $37.99M | $73.44M |
| Cash & Short-Term Investments | $155.6M | $168.0M | $286.5M | $311.6M |
| Other Current Assets | $2.01M | $2.18M | -- | $1.88M |
| Total Current Assets | $165.7M | $177.7M | $289.4M | $316.4M |
| Property, Plant & Equipment, Net | $979K | $1.07M | $1.17M | $1.37M |
| Other Non-Current Assets | $0 | $0 | $0 | $256K |
| Total Non-Current Assets | $4.73M | $5.39M | $1.17M | $14.14M |
| Total Assets | $170.5M | $183.1M | $290.6M | $330.5M |
| Accounts Payable | $3.95M | $2.55M | $7.50M | $3.11M |
| Total Current Liabilities | $18.09M | $12.45M | $33.11M | $31.02M |
| Total Non-Current Liabilities | $1.35M | $1.90M | $0 | $12.03M |
| Total Liabilities | $19.45M | $14.34M | $33.11M | $43.05M |
| Total Debt (incl. Leases) | $3.77M | $4.33M | -- | $14.11M |
| Common Stock | $36K | $35K | -- | $0 |
| Retained Earnings | -$55.93M | -$24.58M | -- | $0 |
| Accumulated Other Comp. Income | $0 | $0 | -$146K | -$24K |
| Total Stockholders' Equity | $151.0M | $168.8M | $257.5M | $287.5M |
| Total Equity | $151.0M | $168.8M | $257.5M | $287.5M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M | -$47.20M |
| Depreciation & Amortization | $92K | $105K | $125K | $140K | $142K | $146K |
| Stock-Based Compensation | $8.90M | $8.32M | $11.50M | $9.85M | $7.66M | $7.75M |
| Operating Cash Flow | -$17.05M | -$31.92M | -$32.56M | -$30.69M | -$38.64M | -$45.01M |
| Capital Expenditure | $0 | -$25K | -$17K | -$12K | -$39K | -$35K |
| Free Cash Flow | -$17.05M | -$31.94M | -$32.58M | -$30.70M | -$38.68M | -$45.04M |
| Purchases of Investments | $0 | $0 | $0 | -$19.66M | -$54.21M | -$122.5M |
| Investing Cash Flow | $0 | -$25K | $34.98M | $103.3M | $36.40M | $14.85M |
| Financing Cash Flow | $4.66M | -$48.51M | $7.85M | -$7.06M | -$52.10M | $5.72M |
| Net Change in Cash | -$12.39M | -$80.45M | $10.27M | $65.53M | -$54.34M | -$24.44M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.16x | 14.28x | 8.74x | -- | -- | -- |
| Quick Ratio | 8.60x | 13.50x | 8.65x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.03x | -- | -- | -- | -- |